Experienced investment and operating executive focused on growth-stage technology and healthcare companies, with transactional experience across venture capital, M&A and corporate strategy. Robyn L. Clarke brings sector diligence, board-level experience and capital-raising acumen to portfolio management and corporate development roles, often advising on go-to-market scaling, capital structure and investor relations for mid-market firms.
Experienced investment and operating executive focused on growth-stage technology and healthcare companies, with transactional experience across venture capital, M&A and corporate strategy. Robyn L. Clarke brings sector diligence, board-level experience and capital-raising acumen to portfolio management and corporate development roles, often advising on go-to-market scaling, capital structure and investor relations for mid-market firms.
Growth-stage, sector-focused investor who prioritizes capital-efficient scaling in technology and healthcare businesses. Emphasizes rigorous diligence, board-level governance and capital structure design to derisk expansion while preserving upside. Prefers staged equity and strategic follow-on allocations tied to go-to-market milestones, revenue inflection and clinical or product validation. Combines transactional experience in VC, M&A and corporate strategy with hands-on operating support for management on commercialization, investor relations and exit positioning over a multi-year horizon.
Growth-stage, sector-focused investor who prioritizes capital-efficient scaling in technology and healthcare businesses. Emphasizes rigorous diligence, board-level governance and capital structure design to derisk expansion while preserving upside. Prefers staged equity and strategic follow-on allocations tied to go-to-market milestones, revenue inflection and clinical or product validation. Combines transactional experience in VC, M&A and corporate strategy with hands-on operating support for management on commercialization, investor relations and exit positioning over a multi-year horizon.
| Trades 390 | Longs Won 263/390 67% | Profit Factor 41.87 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $2.47M |
| Average Win $522,319.66 | Best Trade (Jul 16) $40.52M | Sharpe Ratio -10.97 |
| Average Loss -$25,834.68 | Worst Trade (Dec 31) -$878,634.14 | Z-Score 0.83 (59.51%) |
| Commissions $0 | Avg. Trade Length 1y 1m 1w 6d | Expectancy $343,818.12 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.23% |
| Consecutive Losing Trades | 19,608 | 17,647 | 15,686 | 13,725 | 11,765 | 9,804 | 7,843 | 5,882 | 3,922 | 1,961 |